Business

Median Technologies to Participate in Several Investor Conferences in May and June 2025

SOPHIA ANTIPOLIS, France, May 06, 2025--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today that the Company will participate in upcoming investor conferences in May and

articleMedian TechnologiesMay 6, 20252/company/median-technologies/news/median-technologies-to-participate-in-several-investor-conferences-in-may-and-june-2025-1
Median Technologies to Participate in Several Investor Conferences in May and June 2025

About this update from Median Technologies

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1240,"height":461,"url":"https://media.zenfs.com/en/business-wire.com/6ac01fd3a75a5eb3f2b5ef6bb0600e78"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D71mbeBcj5B8yCNBxLMrwA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM1NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6ac01fd3a75a5eb3f2b5ef6bb0600e78","width":960,"height":357},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/iqBlCkiGjfHY6AYGE0JeVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04OTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/6ac01fd3a75a5eb3f2b5ef6bb0600e78","width":1200,"height":446}},"lazy":false},{"type":"text","content":"SOPHIA ANTIPOLIS, France, May 06, 2025--(BUSINESS WIRE)--Regulatory News:","length":73,"tagName":"p"},{"type":"text","content":"Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today that the Company will participate in upcoming investor conferences in May and June 2025.","length":474,"tagName":"p"},{"type":"text","content":"Forum Midcaps Gilbert DupontMay 13, 2025 - Paris, France","length":57,"tagName":"p"},{"type":"text","content":"TP ICAP Midcap Annual ConferenceMay 15-16, 2025 - Paris, France","length":64,"tagName":"p"},{"type":"text","content":"Portzamparc Mid & Small Caps ConferenceJune 18-19, 2025 - Paris, France","length":76,"tagName":"p"},{"type":"text","content":"Please get in touch through the respective conference booking systems, if you would like to request a one-on-one meeting with Median management at these events. Conferences are for institutional investors only.","length":210,"tagName":"p"},{"type":"text","content":"About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML...

More updates from Median Technologies

Paris, Franceartificial intelligenceMedianinstitutional investorsimaging servicesBUSINESS WIRE